Results 131 to 140 of about 108,823 (265)

Multi‐Targeting Carnosic Acid Kills Drug‐Resistant Helicobacter pylori With Narrow‐Spectrum Activity

Advanced Science, EarlyView.
Carnosic acid selectively eradicates drug‐resistant Helicobacter pylori through a multi‐targeted mechanism involving urease inhibition, membrane disruption, and biofilm eradication. It exhibits no detectable resistance, potent in vivo efficacy, and minimal impact on gut microbiota, positioning it as a promising narrow‐spectrum lead compound against ...
Yuefan Bai, Hongming Huang, Xudong Hang, Shanwei Hu, Qian Tong, Jingchen Xu, Jia Jia, Hongkai Bi   +7 more
wiley   +1 more source

Ways to improve the negative impact of proton pump inhibitors on biopsy-based test accuracy for Helicobacter pylori detection. [PDF]

Indian J Gastroenterol
Malfertheiner P, Schulz C.
europepmc   +1 more source

One‐Step Preparation of Lanthanide‐Doped Polyurea Multicolor Microspheres for Versatile Fluorescent Applications

Advanced Science, EarlyView.
Lanthanide‐doped polyurea microspheres are prepared via a facile one‐step precipitation polymerization. They exhibit strong hydrogen‐bonding and coordination interactions with excellent properties, including multicolor emission, high quantum yield (75.3%), remarkable stability, redispersibility, and biocompatibility.
Guiyu Zhang, Xiaoxia Yu, Xinhui Wang, Xiang Zheng Kong, Xiangling Gu, Jitao Liu, Shusheng Li, Xiaoli Zhu, Lianbao Cao, Xubao Jiang   +9 more
wiley   +1 more source

Erratum: Reply to "Comment on 'Evaluation of the Long-Term Administration of Proton Pump Inhibitors (PPIs) in the Mineral Nutrient's Bioavailability'". [PDF]

ACS Omega
de Brito AS, do Nascimento AN, Fonseca FLA, Fioroto AM, Petri G, do Nascimento RGV.   +5 more
europepmc   +1 more source

Spatiotemporal Targeting Randle Cycle and Immune Checkpoint for Potent Antitumor Therapy

Advanced Science, EarlyView.
A glucose oxidase‐based nanogel (GOX‐NG) system using catechol‐functionalized alginate, exhibits enhanced tumor penetration, prolonged retention, and sustained glucose depletion in the tumor microenvironment. When combined with a fatty acid oxidation inhibitor, it implements dual metabolic suppression, thereby enhancing ROS‐induced immunogenic cell ...
Yuan Gao, Zijian Gong, Yixuan Fu, Jianan Zheng, Xiao Sang, Binglin Chen, Qinzhi Su, Weiping Gao, Fei Duan, Jinqi Wei, Xuliang Deng, Xinyu Liu   +11 more
wiley   +1 more source

Appropriate prescribing and deprescribing of proton pump inhibitors: New Choosing Wisely Canada toolkit. [PDF]

Can Fam Physician
Bland E, van Zanten SV, Thompson W.
europepmc   +1 more source

Photothermal Amplification via Nanorobotic Swarming Dynamics

Advanced Science, EarlyView.
This study explores a novel approach to enhance photothermal therapy using magnetically regulated microswarms. It details the development of magnetic nanoparticles organized into dynamic structures that improve heat retention and conversion efficiency.
Qinglong Wang, Lin Su, Zhengxin Yang, Yihang Jiang, Haojin Yang, Qianqian Wang, Li Zhang, Ben Wang, Jiajia Wang   +8 more
wiley   +1 more source

Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia. [PDF]

Pharmacol Res Perspect
Quach DT, Huynh TM, Galang AJG, Dao HV, Chirapongsathorn S, Kijdamrongthum P, Khan RA, Ong AM, Cheah WK, Khaira KS, Tan SF, Sollano J, Syam AF, Chua TS, Leelakusolvong S, Lee YY.   +15 more
europepmc   +1 more source

Targeting the HSPA8‐CMA‐ATP6V1A Axis Triggers Lysosomal Hyperacidification and Catastrophic Vacuolation in Prostate Cancer

Advanced Science, EarlyView.
Our experimental evidence supports a model in which ALO targets the HSPA8‐CMA‐ATP6V1A axis to induce lysosomal hyperacidification and initiate osmotic and lipidomic stress. These changes are associated with LMP and loss of lysosomal integrity in prostate cancer cells.
Bingzheng An, Ze Gao, Shuo Chen, Liwei Meng, Chen Zhang, Kefan Song, Haochen Cui, Lei Yan, Zhiqing Fang   +8 more
wiley   +1 more source

Correction: Analysis of proton pump inhibitor-associated drug problems and contributing factors among hospitalized nephrology patients. [PDF]

Front Pharmacol
Song N, Zhang X, Han M, Guan Y.
europepmc   +1 more source